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ABSTRACT.
Purpose: Generic instruments to assess health utilities can be used to express the
burden of health problems in widely used indexes. That is in contrast with what
can be obtained with condition-specific instruments, outcomes are very specific
and diﬃcult to compare across conditions. The purpose of this study was to
assess health and visual outcomes and its determinants in patients with visual
impairment (VI) using the EQ-5D-3L and the Activity Inventory (AI).
Methods: Participants were recruited in diﬀerent hospitals during the PCVIP-
study. A total of 134 patients with acuity 0.30 logMAR or less in the better eye
were interviewed. The AI includes 46 goals split between three objectives: social
functioning, recreation and daily living, and was used to measure visual ability.
The EQ-5D consists of five questions covering one domain each and was used to
provide a measure of health states. Responses to each domain were combined to
produce a single individual index.
Results: The AI and the EQ-5D-3L showed enough discriminatory power between
VI levels (p < 0.001), and their results were strongly correlated r(134) = 0.825,
(p < 0.001). Explanatory factors for visual ability were level of VI in better eye, age
and gender, R2 = 0.43, (p < 0.001). Explanatory factors for the EQ-5D-3L were
level of VI in the better eye, comorbidities and gender, R2 = 0.36, (p < 0.001).
Conclusion: Our results showed that the EQ-5D-3L is useful when character-
izing the burden of VI and to compute, when necessary, quality-adjusted-life-
years (QALY) changes due to VI. However, it is important to consider that the
EQ-5D-3L uses a coarse response scale, assesses a limited spectrum of domains
and is influenced by comorbidities. This might limit its responsiveness to small
changes in visual ability.
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Introduction
Patient-reported outcome measures are
fundamental for evaluation of health
technologies or interventions (Brazier
2007). To perform a complete assess-
ment of the benefits of a health
intervention, it is necessary to provide
evidence of the eﬀect of intervention on
patients’ health status and/or health-
related quality of life. The type of
instrument used to measure outcomes
of health interventions must be
designed to serve the specific require-
ments of the study question or the
proposed application. Instruments to
assess patient-reported outcome mea-
sures can be divided into several cate-
gories; however, the divisions should
not be regarded as rigid or mutually
exclusive (Fitzpatrick et al. 1998). The
present study compares the perfor-
mance of two categories of these mea-
sures, health utility and functional
ability measures, in visually impaired
patients.
Health utility measures express pref-
erences or values attached to individual
health states as a single number. Instru-
ments commonly used to collect data
on utilities include the EuroQol-EQ-5D
(Brooks 1996; Langelaan et al. 2007;
van Hout et al. 2012; Butt et al. 2013),
the SF-6D (Espallargues et al. 2005;
Butt et al. 2013), the Geriatric Depres-
sion Scale (Lyness et al. 1997) and
other rating scale questionnaires.
Health utilities typically are estimated
from time trade-oﬀ (Weinstein et al.
2009) or standard gamble methods
(Drummond et al. 1987), or from one
of several stated-preference methods
(e.g. discrete choice (Kessels et al.
2011), pairwise comparison (Bradley
& Terry 1952), best-worst scaling
1
Acta Ophthalmologica 2017
(Flynn et al. 2007) or iterative bidding
games (Brookshire & Crocker 1981)).
Health utilities are used to provide
estimates of the overall value of health
states to the individual and/or to soci-
ety and are used in cost-utility analyses.
To simplify data collection, all likely
combinations of ratings of the five
items in the EQ-5D-3L, each of which
represents a diﬀerent health state, have
been mapped to community-based
health utilities by a representative sam-
ple of the community population using
a time trade-oﬀ method (Ferreira et al.
2014). Therefore, the EQ-5D-3L can be
administered as a rating scale question-
naire and a utility tariﬀ, corresponding
to the pattern of responses to the five
items, can be looked up in a table (or
estimated from an algorithm). The
assigned utility values then can be used
to estimate quality-adjusted life-years
(QALYs; Rein et al. 2007). However, it
often has been suggested that the EQ-
5D-3L can have unreliable and unre-
sponsive outcomes in the case of visual
disorders (Tosh et al. 2012; Malkin
et al. 2013).
The intent of health utilities is to
have the scale referring only to the
value of health states and not be
disease-specific. The EQ-5D-3L, like
most instruments, do not include items
responsive to the eﬀects of vision dis-
orders when assessing health states. In
the past, there have been attempts to
develop separate vision-related utilities
(Brown et al. 2003), but that approach
has been criticized because it overesti-
mates the utility of vision relative to
that of overall health (Kymes 2008;
Frick & Massof 2009).
Condition-specific (individualized)
health state assessment instruments
have item content targeted to specific
symptoms and/or quality of life conse-
quences, with many allowing respon-
dents to select relevant items and/or
rate the importance of each item
(Fitzpatrick et al. 1998). Self-report
instruments used to assess visual func-
tioning include the National Eye Insti-
tute Visual Functioning Questionnaire
(NEI-VFQ; Mangione et al. 2001), the
Impact of Vision Impairment Ques-
tionnaire (IVI; Weih et al. 2002) and
the Activity Inventory (AI; Massof
et al. 2005a,b, 2007). In our study, the
AI was adopted to estimate person
measures, mostly because it has been
developed and used specifically for
individuals with low vision and we
had access to the item calibration file
(Massof et al. 2005 a,b; Goldstein
et al. 2014). The advantage of using
an instrument calibrated with hundreds
of low-vision individuals is that the
interaction between person’s ‘ability’
and item’s ‘diﬃculty’ can be modu-
lated. A strength of such individualized
self-report instruments is that they
address the concerns of individual
patients rather than impose community
standards that may not be well
informed or well targeted to the patient
population of interest. Although some-
times criticized by strict methodolo-
gists, in the case of assessing the eﬀect
of VI or the impact of low-vision
rehabilitation, it often is necessary to
administer self-report visual function-
ing assessment instruments by inter-
view because of the patients’ vision
limitations.
Given the high and growing preva-
lence and incidence of visual impair-
ments from age-related eye diseases,
policy makers need evidence about the
burden of VI to develop eﬀective and
inclusive public health strategies (Binns
et al. 2012). For example, with the
aging of the population and elevated
risks of adverse health events, it is
necessary to know the impact of vision
impairment on health states and the
cost-utility of low-vision rehabilitation.
In many European countries, Portugal
in particular, these two topics remain
poorly studied. A recent exhaustive
critical review of the relevant literature
concluded that more cost-eﬀectiveness
studies are necessary to understand the
eﬀectiveness of current low-vision reha-
bilitation practices (Binns et al. 2012).
Without evidence of cost-eﬀectiveness
of interventions intended to tackle the
burden of VI, two scenarios are likely:
i) decision makers will reduce the
availability of resources for this pur-
pose or ii) allocated resources might be
poorly managed due to undefined pri-
orities. Therefore, for the correct eval-
uation of the burden of VI it would be
desirable to use generic instruments to
make estimated patient preferences
directly comparable to other health state
preferences.
The use of generic instruments to
access health preferences of visually
impaired people remains uncommon,
but seems necessary. For example,
Malkin and colleagues recently con-
ducted one of the few studies to use a
generic health state instrument, the
EQ-5D-3L, to assess both the health
utility of VI and the impact of low-
vision rehabilitation (Malkin et al.
2013). The authors concluded that the
EQ-5D-3L was unresponsive to low-
vision rehabilitation, a conclusion sup-
ported by the results summarized by
Tosh and colleagues who concluded
that the EQ-5D-3L might have limited
ability to distinguish between groups of
patients, stratified by acuity, suﬀering
from age-related macular degeneration
or diabetic retinopathy (DR) (Tosh
et al. 2012; Malkin et al. 2013). These
studies demonstrate that the use of
health utility measures with visually
impaired patients requires further
investigation, in particular to deter-
mine which factors other than visual
acuity (VA) can influence health utili-
ties in visually impaired people.
The purpose of our study was to
investigate whether the EQ-5D-3L and
the AI have equivalent ability to dis-
criminate between VI categories and
which factors can aﬀect those mea-
sures. We hypothesize that generic
(EQ-5D-3L) and condition-specific
(AI) instruments have diﬀerent abilities
to discriminate between levels of VI
and that each instrument is influenced
by a diﬀerent set of visual and non-
visual factors.
Patients and Methods
Participant recruitment and data
collection
Participants were recruited in three
public hospitals as a part of a study
of prevalence and costs of VI in Por-
tugal (PCVIP-study). Outpatients at
these hospitals with VA, measured with
latest refractive correction prescribed,
in the better seeing eye of 0.30 logMAR
or lower were invited to take part in
face-to-face interviews. Visual acuity
(VA) was assessed using an internally
illuminated ETDRS chart (Lighthouse
International, New York, NY, USA) at
4, 2 or 1 m according with the severity
of their vision loss. The room lights
where extinguished during measure-
ments. Letter-by-letter scoring was
employed to specify final measured
acuity (Ferris et al. 1982).
During interviews, participants were
asked about 16 systemic health prob-
lems detailed in Table A1 in Appendix
that are consistent with those assessed
in other studies (van Nispen et al.
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2009; Morales et al. 2010; Whitson
et al. 2011). Demographic information
and other descriptive information for
our sample of 134 participants are
summarized in Table 2. All question-
naires were administered during the
interview and responses recorded in
our digital platform for further extrac-
tion and analysis.
The present study was conducted in
accordance with the tenets of the Dec-
laration of Helsinki, reviewed and
approved by the ethical commission
for Life Sciences and Health of the
University of Minho and hospitals
ethics committees. Written informed
consent was obtained from all partici-
pants.
Functional reserve given by the Activity
Inventory (AI)
The AI is an adaptive visual function
questionnaire designed to provide an
individualized assessment of diﬃcul-
ties of a visually impaired respondent
when performing valued activities.
The AI consists of a hierarchal struc-
ture in which specific cognitive and
motor vision-dependent tasks (e.g.
pouring or mixing without spilling)
underlie more global goals (e.g.
preparing meals). Disabilities, or
activity limitations according to the
World Health Organization’s Interna-
tional Classification of Functioning,
occur when an individual reports
abnormal diﬃculties in achieving
important goals (van Leeuwen et al.
2015). Diﬃculties achieving a goal are
said to depend on the diﬃculty expe-
rienced in the tasks that underlie each
goal (Massof et al. 2005). The inves-
tigators translated the AI into Por-
tuguese (Hern!andez-Moreno et al.
2015). In the Portuguese version, 46
goals divided among three objectives
(social functioning, recreation and
daily living) were used. Respondents
first rated the importance of each goal
with four possible responses ranging
from ‘not important’ to ‘very impor-
tant’. Goals rated ‘not important’
were skipped, for goals rated ‘slightly
important’ or above participants were
asked to rate the goal’s diﬃculty on a
five-point scale ranging from ‘not
diﬃcult’ to ‘impossible to do’. The
‘diﬃculty’ responses were Rasch anal-
ysed to produce a continuous measure
of visual ability given by the variable
‘person measure’ (Program WINSTEPS,
v3.9; Winsteps.com). We use the term
‘visual ability’ to define the overall
ability to perform activities that
depend on vision. Visual ability is
likely to be aﬀected by other condi-
tions apart from VI such are chronic
pain, fatigue or depression (Tabrett &
Latham 2011).
Utility values given by the EQ-5D-3L
The EQ-5D-3L is a generic instrument
for preference-based measures of
health and is expected to provide a
measure of health status (Brooks 1996;
Dolan 1997). The EQ-5D-3L consists
of five questions, each describing a
diﬀerent health state domain. The five
domains are mobility (D1), self-care
(D2), usual activities (D3), pain or
discomfort (D4) and anxiety or
depression (D5). Diﬃculties in each
domain are classified using a three-
point scale: 1 = ‘no problems’,
2 = ‘some problems’ and 3 = ‘extreme
problems or unable’. A respondent’s
overall health state is then defined by a
vector representing the level for each
domain; the combination of answers
to five domains can generate 243 (35)
unique vectors representing overall
heath states. For example, the heath
state vector [11111] would be gener-
ated by someone who does not have
diﬃculty in any domain, whilst [32211]
would be the responses of someone
unable to move, some problems in
self-care and usual activities and no
problems in the last two domains.
Each response vector is then trans-
formed to a health utility using the
EQ-5D-3L index for which 0 corre-
sponds to a state over which immedi-
ate death is preferred and 1
corresponds to the state of ‘perfect
health’. A negative value would corre-
spond to a health state ‘worse than
dead’. Utility index values used here
were obtained from Ferreira and
colleagues who published community
tariﬀs for the EQ-5D-3L in the
Portuguese population (Ferreira et al.
2014). During the questionnaire admin-
istration, clear instructions were given
to consider diﬃculties associated with
VI.
Categories of visual impairment (VI)
Visual impairment (VI) was categorized
according to the guidelines of the Inter-
national Council of Ophthalmology
using VA intervals on a logMAR scale
(International-Council-of-Ophthalmol-
ogy 2002). In a logMAR scale, acuity
can be calculated by adding the number
of letters read considering a score of
0.02 per correct letter. For example, in
an ETDRS chart designed to measure
distance VA at 4 m, the top line corre-
sponds to acuity 1.0 logMAR. Letters
can be used to compute acuity using the
formula: VA = 1.1–0.02xNL, where
NL represents the number of letters
read (Table 1).
Data analysis
Variables were tested for normality
using the Kolmogorov–Smirnov test.
ANOVA was used for multiple compar-
isons, and t-test was used to compare
two distributions when the variables
were normally distributed. Kruskal–
Wallis or Mann–Whitney U tests were
used for comparisons when variables
failed normality tests. The null hypoth-
esis was rejected for a values <0.05,
when necessary Bonferroni correction
was applied (0.05/number-of-compari-
sons). Associations between variables
were tested with Pearson correlations
when both variables were continuous
and Spearman’s rank-order correlation
when any of the variables was ordinal.
Descriptions of correlations ranged
from ‘very weak’ (0.0–0.19) to ‘very
strong’ (0.8–1) using Swinscow’s clas-
sifications (Swinscow 1997). Vision-
specific tools for quantifying visual
ability and generic utility measures
need to be compared with caution.
Table 1. Definition of level of visual impairment used to divide participants into groups.
Category description Lower limit (Visual acuity)
Upper limit
(Visual acuity)
Category
number
No visual impairment 0.30 logMAR (0.5 decimal) !0.30 logMAR 0
Minor VI 0.50 logMAR (0.32 decimal) 0.32 logMAR 1
Moderate VI 1.00 logMAR (0.10 decimal) 0.52 logMAR 2
Severe VI 1.30 logMAR (0.05 decimal) 1.02 logMAR 3
Profound VI/Blind 3.0 logMAR (0.00 decimal) 1.32 logMAR
3
Acta Ophthalmologica 2017
But comparisons have been tried in the
past because they are necessary to
gather information about the overall
impact of vision loss in health (Espal-
largues et al. 2005; Crewe et al. 2011).
To investigate whether final scores of
our instruments were associated with
the same factors, we conducted a
regression analysis using as explana-
tory factors: age, gender, VI level in the
better and in the worse eye and number
of comorbidities. We included the level
of VI in the worse eye because a study
from Finger and colleagues in 2013 has
shown that this could be relevant to
explain reported health states, and we
wanted to test this in both instruments
used (Finger et al. 2013).
Results
The ratio of male to female partici-
pants was 0.97. The median age of
participants was 65.5 years (IQR:
55.7–74.2), five participants were
<18 years old. For minors, when nec-
essary, parents or guardians served as
proxies for the interview. The median
acuity in the better eye for the sample
was 0.54 logMAR (IQR: 0.38–0.85)
and was 1.02 logMAR (IQR: 0.64–
1.68) for the worse eye, a more detailed
summary is given in Table 2.
Results of visual ability scores
Rasch analysis of AI diﬃculty ratings
generates a single interval-scaled value
for each person, the ‘person measure’,
for which higher values correspond to
higher levels of visual ability. The mean
visual ability person measure across all
participants was 0.17 logit (SD = 1.99).
Table 2 provides a summary of these
results, and the distribution of visual
ability person measures for diﬀerent
age groups is shown in Fig. 1. A three-
dimensional scatter plot of visual
ability person measures as a function
of logMAR acuity in the better eye
and in the worse eye is shown in Fig. 2.
The diﬀerence between visual ability
person measures for diﬀerent groups,
defined by the VA in the better eye,
was statistically significant, F(2,131) =
39.57, (p < 0.001; Bonferroni correc-
tion applied). Similar results for other
factors are summarized in Table 2. For
VI groups 1 and 2, the mean diﬀerence
between visual ability person measures
was 1.54 logits (p < 0.001); for groups
1 and 3, the mean diﬀerence was 3.30
logits (p < 0.001); and for groups 2 and
3, the mean diﬀerence was 1.76 logits
(p < 0.001). There was a moderate
negative correlation between logMAR
acuity in the better seeing eye and
visual ability person measures, r
(134) = !0.573 (p < 0.001). This result
shows that higher levels of VI given by
acuity were associated with lower
visual ability person measures.
Results for health states
The most commonly observed health
state vectors for the EQ-5D-3L were
[11111] (index of 1.000) and [22222]
(index of 0.288), reported by 14 partic-
ipants each. The 10 most common
health state vectors are summarized in
Table A2 in Appendix. The mean
EQ-5D-3L index for the entire sample
was 0.442 (SD = 0.311), comparisons
between groups are given in Table 2. A
3-D scatter plot of the EQ-5D-3L index
as a function of logMAR VA in the
better eye and the number of
comorbidities is shown in Fig. 3. The
diﬀerences between EQ-5D-3L index
for diﬀerent VI groups, based on the
acuity of the better eye, tested with
ANOVA, were statistically significant,
F(2,131) = 24.05 (p < 0.001). Post hoc
tests revealed that for VI groups 1 and
2 the mean diﬀerence was 0.203
(p < 0.001), for groups 1 and 3 the
mean diﬀerence was 0.436 (p < 0.001),
and the mean diﬀerence between
groups 2 and 3 was 0.233 (p = 0.001).
There was a moderate negative corre-
lation between logMAR acuity in the
better eye and EQ-5D-3L index, r
(134) = !0.506 (p < 0.001). Higher
values of logMAR (i.e. lower visual
acuities) are associated with lower EQ-
5D-3L index. A partial correlation
between age (controlling for acuity in
the better eye) and EQ-5D-3L index
also was observed, r(131) = !0.183
Table 2. Demographic characteristics of the participants and descriptive statistics.
Variable N
EQ-5D index
mean [SD]
Visual ability
(logits) mean
[SD]
VA better
(logMAR)
median [IQR]
VA worse
(logMAR)
median [IQR]
Gender
Male 66 [49%] 0.518 [0.281] 0.45 [2.03] 0.63 [0.31] 1.30 [0.84]
Female 68 [51%] 0.368 [0.322] !0.09 [1.92] 0.75 [0.58] 1.24 [0.76]
p Value – 0.005 0.11 0.77 0.73
Age (years)
Below 40 10 [8%] 0.509 [0.297] 0.24 [1.38] 0.81 [0.56] 1.16 [0.78]
41–80 116 [86%] 0.433 [0.321] 0.22 [2.07] 0.69 [0.47] 1.25 [0.81]
Above 80 8 [6%] 0.491 [0.138] !0.59 [1.02] 0.54 [0.26] 1.68 [0.72]
p Value – 0.69 0.53 0.51 0.20
Level of VI better eye
1 60 [45%] 0.596 [0.281] 1.34 [1.85] 0.37 [0.06] 0.88 [0.63]
2 50 [37%] 0.393 [0.270] !0.20 [1.29] 0.69 [0.13] 1.27 [0.65]
3 24 [18%] 0.160 [0.220] !1.96 [1.38] 1.50 [0.52] 2.26 [0.58]
p Value – <0.001 <0.001 <0.001 <0.001
Level of VI worse eye
1 20 [15%] 0.669 [0.261] 1.85 [1.76] 0.35 [0.04] 0.40 [0.06]
2 46 [34%] 0.511 [0.301] 0.80 [1.63] 0.50 [0.15] 0.76 [0.15]
3 68 [51%] 0.329 [0.282] !0.74 [1.79] 0.92 [0.55] 1.87 [0.69]
p Value – <0.001 <0.001 0.001 <0.001
Cause of VI
DR 54 (40) 0.410 [0.309] !0.26 [1.71] 0.74 [0.47] 1.33 [0.81]
Other RD 30 (22%) 0.421 [0.341] 0.57 [2.33] 0.66 [0.35] 1.32 [0.83]
AMD 15 (11%) 0.529 [0.296] 0.38 [1.83] 0.50 [0.26] 1.23 [0.74]
Glaucoma 10 (7%) 0.310 [0.258] !0.53 [1.68] 0.66 [0.31] 1.32 [0.88]
Corneal disease 8 (6%) 0.490 [0.322] 0.15 [2.23] 0.58 [0.37] 1.25 [0.97]
Cortical/ON 13 (10%) 0.495 [0.299] 0.59 [2.27] 1.03 [0.81] 1.16 [0.81]
Cataract 4 (3%) 0.719 [0.162] 2.21 [1.21] 0.34 [0.04] 0.69 [0.34]
p Value – 0.22 0.08 0.019 0.56
Number of comorbidities
0–3 100 [75%] 0.479 [0.294] 0.28 [1.85] 0.68 [0.39] 1.28 [0.76]
3–6 34 [25%] 0.333 [0.334] !0.13 [2.36] 0.73 [0.65] 1.37 [0.90]
p Value – 0.017 0.30 0.31 0.85
DR = diabetic retinopathy; RD = Retinal disease; ON = optic nerve; AMD = Age-related
macular degeneration.
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(p = 0.035). The negative correlation
indicates that the index tends to reduce
with age.
Comparison between instruments
We observed a strong correlation
between the EQ-5D-3L index and
visual ability person measures, r(134)
= 0.779 (p < 0.001).
Factors associated with visual ability
person measures
Multiple linear regression analysis
showed that gender, age, level of VI
in the better eye and in the worse eye
are significant independent predictors
of visual ability person measures. Basic
descriptive statistics and regression
coeﬃcients are summarized in Table 3;
the four predictors account for 45% of
the variance in visual ability person
measures. Those with higher VA in the
better eye have higher visual ability.
The typical diﬀerence between VI
groups (stratified by acuity in the better
eye) was approximately 1.4 logits
(unstandardized beta coeﬃcients in
Table 3). Level of VI in the worse eye
does not achieve statistical significance
in our model (p = 0.053).
Factors associated with EQ-5D-3L index
Multiple linear regression analysis
showed that gender, level of VI in the
better eye and number of comorbidities
are significant independent predictors
of EQ-5D-3L results. Basic descriptive
statistics and regression coeﬃcients are
summarized in Table 4; the three pre-
dictors account for 36% of the variance
in the EQ-5D-3L index. In agreement
with the visual ability person measures,
those with higher acuity in the better
eye had shown higher EQ-5D-3L
scores. The diﬀerence between sequen-
tial groups of VI would be approxi-
mately 0.2. Females and those with
four or more comorbidities have lower
EQ-5D-3L scores.
Figure 4 shows response patterns for
the EQ-5D-3L domains when the
group with 0–3 comorbidities was
compared with the group with 4–6
comorbidities; the number of people
with ‘no problems’ was reduced in all
domains. With 4–6 comorbidities, the
number of cases with some problems
increased in D1 (mobility) and D4
(pain and discomfort). Also, with 4–6
comorbidities, there was an increased
percentage of extreme problem for all
but D1. The contrast is particularly
visible in D3 (usual activities) and D5
(anxiety and depression).
Discussion
This study was conducted to determine
which factors aﬀect patient-reported
measures of health utilities, estimated
from EQ-5D-3L responses, and of
visual ability, estimated from diﬃculty
ratings of activity goals in the AI. Both
measures were related positively to VI
in the better eye. Regression analysis
suggests that EQ-5D-3L utility index is
associated with both, VI level in the
better eye and the number of reported
comorbidities. Visual ability measures
are associated with age and VI in the
better eye. Both utility and ability
measures are associated with gender.
These results are in agreement with the
initial hypothesis that expected a dif-
ferent set of predictors for each of the
two measures. However, contrary to
initial expectations, results from both
instruments were associated with VI in
the better eye.
Our results indicate that the EQ-5D-
3L index is responsive to visual impair-
ments. In that sense, our results agree
with previous observations by other
investigators using the EQ-5D-3L
(Langelaan et al. 2007; van Nispen
et al. 2009) and other health utilities
instruments (Crewe et al. 2011; Briesen
et al. 2014). In contrast to our results, a
study by Lloyd and colleagues found
inconsistent associations of utilities
with VA in patients with DR (Lloyd
et al. 2008). Lloyd obtained lower
scores for patients with acuity 6/12 to
6/18 than for patients with acuity 6/24
to 6/36. As suggested by Tosh et al.
(2012), the association of EQ-5D-3L
utility indices with visual impairments
might depend on the visual disorder
studied. However, our study included a
range of disorder diagnoses and we
found no evidence of disorder
Below
 41
0
10
20
41-80
Age group (years)
0
10
20
N
um
be
r o
f c
as
es
Above 80
–6 –4 –2 0 2 4 6
Visual Ability (logits)
0
10
20
Fig. 1. Histogram showing the distribution of visual ability person measure per age group in the
all sample.
5
Acta Ophthalmologica 2017
diagnosis dependence. van Nispen
et al. (2009) have found index results
slightly higher than ours in an obser-
vational study applying the EQ-5D-3L
in mixed causes of VI. Diﬀerences
between our results and van Nispen’s
might be explained by the distribution
of causes of VI, level of acuity in the
better eye and age. The main cause of
VI in their study was age-related mac-
ular degeneration, and in our study it
was DR. Also, our IQR of acuities was
wider and our participants overall were
younger compared to the van Nispen
et al. study (median age of 65 years for
our study versus 78 years for their
study). As reported by others, younger
subjects with VI might feel, for exam-
ple, more often anxious or depressed
(Langelaan et al. 2007; van Nispen
et al. 2016). As shown in Table A2 in
Appendix, 19 of our participants
reported ‘severe depression or anxiety’
that was never reported in the van
Nispen et al. study’s top ten health
states. Another additional explanation
for the diﬀerence between studies is
that lower EQ-5D-3L utility indices are
expected in Portugal than in the
Netherlands because of diﬀerences in
community calibrations. Ferreira and
colleagues found that there is discrep-
ancy between the EQ-5D-3L index in
Portugal and other countries. Ferreira
found mean absolute diﬀerences rang-
ing from 0.090, compared with Spain,
to 0.251, compared with the USA
(Ferreira et al. 2014).
Gender and the numbers of comor-
bidities were predictors of the EQ-5D-
3L index. The eﬀect of gender that we
found in our multiple regression is not
commonly observed; however, Lange-
laan et al. (2007) did report signifi-
cance of gender and that is in line with
what has been found in the general
population in some countries
(Burstr€om et al. 2001). Comorbidities
also had an eﬀect in the EQ-5D-3L;
however, during the questionnaire
administration clear instructions were
given to consider diﬃculties caused
only by VI. Generic questionnaires
use broad questions and they are likely
to capture eﬀects of other health prob-
lems. Some studies have shown that
people after stroke tend to report lower
EQ-5D-3L scores than people with VI
(Langelaan et al. 2007). In our case,
sometimes these two conditions (VI
and stroke) were present in the same
participant. As shown in Fig. 4, there
are noticeable changes in response
patterns when comparing people with
four or more comorbidities with people
with three or less. The lack of control
for type and number of comorbidities
can be a problem when applying the
EQ-5D-3L. Vision impairment has the
potential to influence EQ-5D-3L
responses only to four of the five
domains: anxiety-depression, mobility,
self-care and usual activities. Given the
coarseness of the response scale, it is
likely that vision impairment must be
strong to aﬀect the response. Eﬀects of
comorbidities combine with VI eﬀects
to produce the final response.
In agreement with previous studies,
utility results were independent of the
cause of VI and age (van Nispen et al.
2009; Crewe et al. 2011; Briesen et al.
2014). However, we observed a partial
correlation (controlling to acuity in the
better eye) between EQ-5D-3L index
and age that pointed to some eﬀect of
age in this index. Langelaan and col-
leagues reported lower scores for peo-
ple <41 years compared with people
aged 41 years or older. They attributed
their result to problems in social inclu-
sion faced by young people with VI
such as finding a job (Langelaan et al.
2007). Contrary to Langelann’s expla-
nation, we consider plausible that
lower scores with increasing age would
be due to unemployment or early
retirement that increase diﬃculties in
dealing with vision loss (Senra et al.
2011, 2015). Our results indicate that
the EQ-5D-3L is an instrument that
can be used to assess the impact of VI
and to compute other important mea-
sures such as quality-adjusted life-years
(QALY). However, its application
requires caution because VI can aﬀect
domains that are not currently
included in the questionnaire such as
sleep quality or concentration (Flynn-
Evans et al. 2014; Jelsma & Maart
2015).
Results of the AI provide a compre-
hensive assessment of the impact of VI.
Our results for the AI are in agreement
with what other authors found for
patients with VI due to various causes
(Pearce et al. 2011; Goldstein et al.
2014) or VI caused by specific eye
diseases such as DR (Dunbar et al.
2012). The eﬀect of age on visual ability
obtained with the AI has been found
before and has been explained by the
overall physical functioning decline
explained by aging (Goldstein et al.
Fig. 2. Scatter plot showing the distribution of visual ability according with acuity in the better
and worse eye.
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2014). In addition, the sensitivity of the
AI to the eﬀect of VI in the worse eye is
a further explanation why lower visual
ability scores were obtained in the
older group. Vision in the worse eye
of participants with 81 years or older
was typically very poor, range 0.8–2.7
logMAR, whilst for the other age
groups was slightly higher, range
0.32–2.7 logMAR. It is understandable
that when vision in one eye is reduced
the visual field tends to be also com-
promised; severe VI in the second eye is
likely to increase activity limitations
such as mobility due to constriction of
the visual field (Finger et al. 2013).
This eﬀect seems to be captured by our
results because a detrimental eﬀect of
the level of VI in the worse eye in visual
ability was only observed when VI in
the worse eye was 3 (severe VI or
blindness).
We acknowledge that a higher num-
ber of participants would have been
ideal to have, for example, more sub-
jects in the group with 81 years or
more. Another advantage of a bigger
sample would be a more detailed anal-
ysis by type of eye disease and type of
comorbidity. A limitation that might
Fig. 3. Scatter plot showing the distribution of the EQ-5D index according with acuity in the
better eye and number of comorbidities.
Table 3. Factors associated with visual ability scores (person measure) in a multivariate
regression model with forward selection of variables.
Predictor
Un-standardized
beta
coeﬃcients p Value
Standard
error
Intercept 1.978 <0.001 0.256
Gender
Male* –
Female !0.691 0.009 0.264
Age
Below 80* –
Above 80 !1.495 0.010 0.576
VI better eye
1* –
2 !1.397 <0.001 0.307
3 !2.940 <0.001 0.442
VI worse eye
1* –
2† –
3 !0.622 0.053 0.318
* Reference category.
† Result collapsed with the reference category; excluded variables: comorbidities; multiple R-
squared: 0.45; adjusted R-squared: 0.43; F(5,128) = 21.1; p-value <0.001.
Table 4. Factors associated with EQ-5D index
in a multivariate regression model with for-
ward selection of variables.
Predictor
Un-
standardized
beta
coeﬃcients p Value
Standard
error
Intercept 0.726 <0.001 0.042
Gender
Male* –
Female !0.140 0.001 0.043
VI better eye
1* –
2 !0.242 <0.001 0.048
3 !0.439 <0.001 0.060
Comorbidity
0–3* –
3–6 !0.175 <0.001 0.050
* Reference category; excluded variables: age,
level of VI worse eye; multiple R-squared: 0.38;
adjusted R-squared: 0.36; F(4,129) = 20.01; p
Value <0.001.
Fig. 4. Change in the percentage of partici-
pants reporting no problems (blue bars), some
problems (orange bars) or extreme problems
(grey bars) when comparing the group with 0–
3 comorbidities with the group 4–6 comorbidi-
ties in each of the five domains of the EQ-5D.
D1 (mobility); D2 (self-care); D3 (usual activ-
ities); D4 (pain and discomfort); D5 (anxiety
and depression).
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reduce our explanatory power is that
factors associated with scores do not
follow a rectangular distribution.
To conclude, our results show that
the EQ-5D-3L is useful when charac-
terizing the burden of VI and, when
necessary, to compute QALY associ-
ated with VI. Given the coarseness of
the response scale of the EQ-5D-3L,
the limited spectrum of domains
assessed (Jelsma & Maart 2015) and
the influence of comorbidities, it might
be of limited use in vision rehabilitation
(Malkin et al. 2013). Further studies
are necessary to investigate whether the
new versions of the instrument are able
to improve these limitations.
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Table A1. List of comorbidities used for the
interview.
1. Cancer
2. Diabetes
3. Heart condition
4. Hypertension
5. Musculoskeletal disorder
6. Pulmonary disease
7. Stroke or brain haemorrhage
8. Hearing impairments
9. Thyroid condition
10. Psychological problems
11. Neurologic problems
12. Chronic allergies
13. Gastrointestinal condition
14. Liver disease
15. Autoimmune diseases
16. Endocrine condition
Table A2. Most frequently reported health
states.
Health
state
EQ-5D
index
No. of
participants Percentage
11111 1.000 14 10
22222 0.288 14 10
22223 0.129 10 7
21223 0.287 9 7
11112 0.767 7 5
11121 0.694 7 5
21222 0.446 7 5
21221 0.482 6 4
11122 0.657 5 4
21111 0.695 5 4
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